GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Thermogenesis Holdings THMO · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2023

Revenue

$9.4m

FY2014FY2023

Net income

−$18.0m

FY2014FY2023

Free cash flow

−$5.5m

FY2014FY2023

Shareholders' equity

−$3.6m

FY2014FY2023

Income statement

Fiscal years

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Revenue$9.4m$10.5m$9.3m$9.7m$13.0m$9.7m$14.5m$11.9m$16.0m$16.0m
Research and development$1.3m$1.7m$2.2m$2.5m$2.4m$3.0m$2.5m$3.2m$5.9m$3.5m
Operating income−$8.6m−$6.2m−$7.2m−$8.9m−$4.7m−$43.5m−$9.4m−$10.9m−$14.9m−$9.0m
Net income−$18.0m−$11.3m−$11.4m−$16.4m−$9.5m−$39.7m−$29.1m−$18.6m−$14.9m−$8.6m
Diluted earnings per share-4.97-10.87-42.99-64.27-74.08-726.07-1,270.52-848.77-3,228.70-42.83

Balance sheet

At each fiscal year end

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Total assets$11.2m$19.4m$20.7m$20.9m$15.2m$14.6m$46.9m$49.9m$50.8m$62.9m
Cash and short-term investments$2.0m$4.2m$7.3m$7.2m$3.2m$2.4m$3.6m$5.8m$3.4m$14.8m
Total liabilities$14.8m$16.1m$17.3m$15.0m$14.3m$7.9m$16.1m$17.6m$15.9m$14.2m
Debt$10.6m$10.4m$10.5m$7.7m$5.7m$3.4m$7.7m$3.9m$3.2m$599,000
Shareholders' equity−$3.6m$3.3m$3.4m$5.9m$916,000$6.7m$30.8m$32.3m$34.9m$48.7m
Shares outstanding4m1m0m0m0m0m0m0m0m0m

Cash flow

Fiscal years

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Cash from operations−$3.7m−$7.3m−$6.6m−$14.4m−$3.3m−$7.0m−$7.2m−$9.6m−$10.6m−$7.8m
Capital spending−$1.7m−$400,000−$93,000−$23,000−$182,000−$1.2m−$375,000−$710,000−$587,000−$402,000
Free cash flow−$5.5m−$7.7m−$6.7m−$14.4m−$3.4m−$8.2m−$7.6m−$10.3m−$11.2m−$8.2m
Dividends paid——————−$3.6m−$17.0m——

Latest quarters

By quarter end

Mar 2024Dec 2023Sept 2023Jun 2023Mar 2023Dec 2022Sept 2022Jun 2022
Revenue$2.7m$2.4m$2.2m$2.3m$2.6m$2.7m$2.1m$3.0m
Operating income−$557,000−$2.2m−$1.6m−$1.7m−$1.0m−$1.5m−$2.0m−$1.4m
Net income−$1.9m−$7.0m−$3.6m−$2.3m−$5.1m−$3.4m−$3.2m−$2.7m
Diluted earnings per share-0.46-1.94-1.00-0.62-1.41-3.31-3.12-2.59
Cash from operations—−$2.0m———−$1.0m−$1.0m—
Total assets$10.1m$11.2m$15.9m$17.6m$19.8m$19.4m$20.1m$21.3m
Cash and short-term investments$1.2m—$4.0m$4.5m$5.9m$4.2m$3.9m$4.0m
Debt$4.2m—$5.3m$7.2m$6.9m$6.7m$6.1m$6.3m
Shareholders' equity$975,000−$1.7m$4.6m$3.8m$6.1m$4.3m$5.1m$6.2m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-1.0%-0.5%-6.2%
Operating income-1.1%-27.7%10.9%
Net income3.2%-14.7%19.3%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-74.3%-79.4%-128.4%-91.5%
Net margin-146.8%-146.2%-172.1%-130.6%

Valuation history

At each fiscal year end

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Price to earnings-0.0-0.0-0.1-0.1-0.1—-0.0-0.0-0.0-2.5
Price to sales0.00.00.10.10.10.00.10.10.01.4

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return0%-100%-88%-85%-41%44%9%-91%5%-26%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 45-to-1 reverse split · 22 Dec 2022
  • 10-to-1 reverse split · 5 Jun 2019
  • 20-to-1 reverse split · 7 Mar 2016
  • 4-to-1 reverse split · 27 Aug 2010
  • 2-to-1 reverse split · 17 Jun 1996

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.